Evidence That Nasal Insulin Induces Immune Tolerance to Insulin in Adults With Autoimmune Diabetes

Fourlanos, S; Perry, C; Gellert, SA; Martinuzzi, E; Mallone, R; Butler, J; Cohnan, PG; Harrison, LC

Author(s): Fourlanos, S; Perry, C; Gellert, SA; Martinuzzi, E; Mallone, R; Butler, J; Cohnan, PG; Harrison, LC;
Details: Publication Year 2011-04,Volume 60,Issue #4,Page 1237-1245
Journal Title: DIABETES
Publication Type: Journal Article
Abstract: OBJECTIVE-Insulin in pancreatic beta-cells is a target of autoimmunity in type 1 diabetes. In the NOD mouse model of type 1 diabetes, oral or nasal administration of insulin induces immune tolerance to insulin and protects against autoimmune diabetes. Evidence for tolerance to mucosally administered insulin or other autoantigens is poorly documented in humans. Adults with recent-onset type 1 diabetes in whom the disease process is subacute afford an opportunity to determine whether mucosal insulin induces tolerance to insulin subsequently injected for treatment. RESEARCH DESIGN AND METHODS-We randomized 52 adults with recent-onset, noninsulin-requiring type 1 diabetes to nasal insulin or placebo for 12 months. Fasting blood glucose and serum C-peptide, glucagon-stimulated serum C-peptide, and serum antibodies to islet antigens were monitored three times monthly for 24 months. An enhanced ELISpot assay was used to measure the T-cell response to human proinsulin. RESULTS-beta-Cell function declined by 35% overall, and 23 of 52 participants (44%) progressed to insulin treatment. Metabolic parameters remained similar between nasal insulin and placebo groups, but the insulin antibody response to injected insulin was significantly blunted in a sustained manner in those who had received nasal insulin. In a small cohort, the interferon-gamma response of blood T-cells to proinsulin was suppressed after nasal insulin. CONCLUSIONS-Although nasal insulin did not retard loss of residual beta-cell function in adults with established type 1 diabetes, evidence that it induced immune tolerance to insulin provides a rationale for its application to prevent diabetes in at-risk individuals. Diabetes 60:1237-1245, 2011
Publisher: AMER DIABETES ASSOC
Keywords: BETA-CELL FUNCTION; RANDOMIZED CONTROLLED-TRIAL; NOD MICE; ORAL INSULIN; T-CELLS; TYPE-1; AUTOANTIBODIES; PROINSULIN; RESPONSES; RISK
Publisher's Version: https://doi.org/10.2337/db10-1360
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2011-04-01 12:00:00